
4.7 Billion Acquisition Fails, Blood Product Industry Stagnates
China National Biotec Group terminated its 4.7 billion RMB acquisition of Pailin Biotech, signaling a shift in the blood products industry's growth logic. The sector is facing severe profit declines and inventory pressure as the era of rapid resource-driven expansion ends.






